Related Experiment Video
Updated: Mar 25, 2026

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
Prevalence of insomnia-related symptoms continues to increase in the Finnish working-age population
Erkki Kronholm1, Timo Partonen1, Mikko Härmä2
1Department of Health, National Institute for Health and Welfare, Turku, Finland.
Abstract:
In 2008, we published epidemiological data from 1972 to 2005 that suggested an increase in insomnia-related symptoms among the working-age population. The results were based on the National FINRISK (FR) Study samples of the Finnish adult population aged 25-64, and on the Finnish Quality of Work Life Surveys (FQWLS), carried out among Finnish salary earners. Both of these ongoing studies have since provided two new estimates of insomnia-related symptoms. Chronic insomnia-related symptoms were 9.0% (95% CI 8.3-9.7), 9.6% (95% CI 8.8-10.4) in FR 2007 and 2012, respectively; and 9.1% (95% CI 8.3-10.0), 9.2% (95% CI 8.4-10.1) in FQWLS 2008 and 2013, respectively. Occasional insomnia-related symptoms were 45.3% (95% CI 44.1-46.6), 42.5% (95% CI 41.1-43.9) in FR 2007 and 2012, respectively; and 40.3% (95% CI 38.8-41.7), 44.8% (95% CI 41.1-43.9) in FQWLS 2008 and 2013, respectively. The new estimates further strengthen the interpretation of the ongoing increase in occasional insomnia-related symptoms among the Finnish general adult population. The increase in occasional symptoms was most prominent among employees. However, chronic insomnia symptoms showed no further increase.
Related Concept Videos
Insomnia
Multiple factors contribute...
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
Management of Insomnia
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Narcolepsy
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

